SENSORION: One-year delay for SENS-401 Phase II results | CORPORATE | EUR2 vs. EUR2.2 (+207%)
SENSORION - CORPORATE | EUR2 vs. EUR2.2 (+207%)One-year delay for SENS-401 Phase II results
Military sites’ ramp-up is taking longer than expected
Civil sites are also impacted due to COVID-19 outbreak
Timing for Cochlear collab and gene therapies remain unchanged
Slight decrease of our FV from EUR2.2 to EUR2.0
Sensorion SA is a France-based company principally engaged in the biopharmaceutical sector. The Company is principally active in the development of targeted therapeutic solutions to treat inner ear diseases. The Company develops also drug treatments, from molecular biology all the way to animal pharmacology, toxicology, and clinical research and therapeutic solutions to treat vestibular deficits. Sensorion SA is a spin-off of the research team Pathophysiology and Therapy of Vestibular Deficits in Montpellier Neuroscience Institute.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.